371 related articles for article (PubMed ID: 9587952)
1. Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers.
Lucas P; Anderson K; Staniforth JN
Pharm Res; 1998 Apr; 15(4):562-9. PubMed ID: 9587952
[TBL] [Abstract][Full Text] [Related]
2. The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols.
Zeng XM; Pandhal KH; Martin GP
Int J Pharm; 2000 Mar; 197(1-2):41-52. PubMed ID: 10704792
[TBL] [Abstract][Full Text] [Related]
3. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
[TBL] [Abstract][Full Text] [Related]
4. What is the role of particle morphology in pharmaceutical powder aerosols?
Chan HK
Expert Opin Drug Deliv; 2008 Aug; 5(8):909-14. PubMed ID: 18712999
[TBL] [Abstract][Full Text] [Related]
5. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
Jetzer MW; Schneider M; Morrical BD; Imanidis G
J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
[TBL] [Abstract][Full Text] [Related]
6. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
7. Formulation and evaluation of insulin dry powder for inhalation.
Mahesh Kumar T; Misra A
Drug Dev Ind Pharm; 2006 Jul; 32(6):677-86. PubMed ID: 16885123
[TBL] [Abstract][Full Text] [Related]
8. Defining the critical material attributes of lactose monohydrate in carrier based dry powder inhaler formulations using artificial neural networks.
Kinnunen H; Hebbink G; Peters H; Shur J; Price R
AAPS PharmSciTech; 2014 Aug; 15(4):1009-20. PubMed ID: 24831088
[TBL] [Abstract][Full Text] [Related]
9. Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery.
Chan HK; Clark A; Gonda I; Mumenthaler M; Hsu C
Pharm Res; 1997 Apr; 14(4):431-7. PubMed ID: 9144727
[TBL] [Abstract][Full Text] [Related]
10. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro.
Srichana T; Martin GP; Marriott C
Eur J Pharm Sci; 1998 Dec; 7(1):73-80. PubMed ID: 9845780
[TBL] [Abstract][Full Text] [Related]
11. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers.
Corrigan DO; Corrigan OI; Healy AM
Int J Pharm; 2006 Sep; 322(1-2):22-30. PubMed ID: 16815654
[TBL] [Abstract][Full Text] [Related]
12. Aerosolisation of beclomethasone dipropionate using spray dried lactose/polyethylene glycol carriers.
Gilani K; Rouholamini Najafabadi A; Barghi M; Rafiee-Tehrani M
Eur J Pharm Biopharm; 2004 Nov; 58(3):595-606. PubMed ID: 15451534
[TBL] [Abstract][Full Text] [Related]
13. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers.
Hassoun M; Ho S; Muddle J; Buttini F; Parry M; Hammond M; Forbes B
Int J Pharm; 2015 Jul; 490(1-2):360-7. PubMed ID: 25987210
[TBL] [Abstract][Full Text] [Related]
14. Modification of electrostatic charge on inhaled carrier lactose particles by addition of fine particles.
Bennett FS; Carter PA; Rowley G; Dandiker Y
Drug Dev Ind Pharm; 1999 Jan; 25(1):99-103. PubMed ID: 10028425
[TBL] [Abstract][Full Text] [Related]
15. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
Marriott C; MacRitchie HB; Zeng XM; Martin GP
Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
[TBL] [Abstract][Full Text] [Related]
16. Critical attributes of fine excipient materials in carrier-based dry powder inhalation formulations: The particle shape and surface properties.
Elsayed MMA; Alfagih IM; Brockbank K; Aodah AH; Ali R; Almansour K; Shalash AO
Int J Pharm; 2024 Apr; 655():123966. PubMed ID: 38452834
[TBL] [Abstract][Full Text] [Related]
17. [Effect of mixing of fine carrier particles on dry powder inhalation property of salbutamol sulfate (SS)].
Iida K; Leuenberger H; Fueg LM; Müller-Walz R; Okamoto H; Danjo K
Yakugaku Zasshi; 2000 Jan; 120(1):113-9. PubMed ID: 10655787
[TBL] [Abstract][Full Text] [Related]
18. The influence of drug morphology on aerosolisation efficiency of dry powder inhaler formulations.
Adi H; Traini D; Chan HK; Young PM
J Pharm Sci; 2008 Jul; 97(7):2780-8. PubMed ID: 17894369
[TBL] [Abstract][Full Text] [Related]
19. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
Le VN; Bierend H; Robins E; Steckel H; Flament MP
Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
[TBL] [Abstract][Full Text] [Related]
20. Performance indicators for carrier-based DPIs: Carrier surface properties for capsule filling and API properties for in vitro aerosolisation.
Faulhammer E; Zellnitz S; Wutscher T; Stranzinger S; Zimmer A; Paudel A
Int J Pharm; 2018 Jan; 536(1):326-335. PubMed ID: 29217472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
